Evidence map›Paper›PMID 41292834›Full record

ArticlebioRxiv : the preprint server for biology2025

EMT activates ER-to-Golgi trafficking through upregulation of REEP2 to promote lung cancer progression.

Kevin Fulp, Oluwafunminiyi Obaleye, Shike Wang, Xin Liu, Jiang Yu, Jonathan M Kurie, Jun Xu, William K Russell, Xiaochao Tan, Guan-Yu Xiao

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kevin FulpDepartment of Toxicology and Cancer Biology, The University of Kentucky College of Medicine, Lexington, Kentucky.
Oluwafunminiyi ObaleyeDepartment of Toxicology and Cancer Biology, The University of Kentucky College of Medicine, Lexington, Kentucky.
Shike WangDepartment of Medicine, Tulane University School of Medicine, Louisiana Cancer Research Center, New Orleans, Louisiana.
Xin LiuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jiang YuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jonathan M KurieDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jun XuDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas.
William K RussellDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas.
Xiaochao TanDepartment of Medicine, Tulane University School of Medicine, Louisiana Cancer Research Center, New Orleans, Louisiana.
Guan-Yu XiaoDepartment of Toxicology and Cancer Biology, The University of Kentucky College of Medicine, Lexington, Kentucky.ORCID 0000-0003-3454-6717

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Interdisciplinary Research Training in Cancer BiologyT32CA165990 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers, KATHLEEN L. O'CONNOR · 2013 to 2026
$3.2M
Regulation of lung cancer metastasis through transcriptional control of the Golgi apparatusR01CA211125 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2017 to 2021
$1.8M
Regulation of Lung Cancer Metastasis by ZEB1R01CA181184 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2014 to 2018
$1.7M
A pro-metastatic secretory program activated by epithelial-to-mesenchymal transitionR00CA249048 · NCI · UNIVERSITY OF KENTUCKY · PI GUAN-YU XIAO · 2024 to 2026
$747k
An actionable secretory program that drives tumor progression in a genetically defined subset of lung squamous carcinomaR03CA280382 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TAN, XIAOCHAO · 2023 to 2024
$158k
NCI NIH HHS P30 CA177558NCI NIH HHS P50 CA070907NCI NIH HHS R00 CA249048NCI NIH HHS R01 CA181184NCI NIH HHS R01 CA211125NCI NIH HHS R03 CA280382NCI NIH HHS T32 CA165990
6 · The paper itself

Abstract

Membrane trafficking governs the transport of molecules to both intracellular and extracellular locations, thereby maintaining cell homeostasis. During cancer progression, alterations in membrane trafficking are frequently observed. However, the mechanisms underlying the dysregulation of membrane trafficking in cancer progression remain largely unresolved. Recent evidence has demonstrated that epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma (LUAD) employs a membrane trafficking program to coordinate cancer cell invasion and immunosuppression in the tumor microenvironment (TME). To further dissect the pro-tumorigenic membrane trafficking program, here we conducted a CRISPR interference (CRISPRi)

Identifiers

PMID41292834
PMCPMC12642484

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.